Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45

Benzinga · 07/07 10:40
Wolfe Research analyst Rudy Li initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform rating and announces Price Target of $45.